Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From CrystalGenomics, Inc.
Asia Deal Watch: Biocytogen Antibody Candidates To Be Evaluated By ADC Therapeutics
Transactions involving Biocon/Zentiva, CrystalGenomics/PanGen, Umoja/IASO, Marinus/Tenacia, Ono/Captor and Daewoong/HitGen plus deals in brief.
Ildong Joins Oral COVID-19 Drug Race Via Shionogi Partnership
Ildong has become the latest Korean pharma firm to start developing an oral COVID-19 drug in the country, potentially competing with Merck and Pfizer’s candidates which are now under approval review locally. The latest co-development deal is also set to expand the market prospects for the antiviral's Japanese originator.
Aptose Picks Up Hanmi’s MKI To Buoy Hematological Cancer Pipeline
Analysts see Hanmi’s clinical-stage asset as fitting well into Aptose's pipeline and providing potential combination therapy benefits for hematological malignancies.
Korean Firms Pursue “Select And Focus” Strategy To Accelerate R&D
South Korean pharma and biotech companies are opting to spin off certain businesses and set up new subsidiaries to speed up R&D progress and tap funding opportunities. The move, which has become more visible in the past few years is in line with global biopharma trends, although the reasons may vary.
- Other Names / Subsidiaries
- CG Pharmaceuticals, Inc.
- Bexpharm Ltd.
- BexpharmKorea Ltd.
- Hwail Pharmaceutical Co., Ltd.
- Palkion, Inc
- CrystalGenomics Inc.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.